Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

Russell serves individual, institutional and advisor clients in more than 40 countries. Russell provides access to some of the world's best money managers. It helps investors put this access to work in corporate defined benefit and defined contribution plans, and in the life savings of individual investors.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in s
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... including the appointment of auditors, its annual and special ... "Meeting") was adjourned, as previously disclosed on March 25, ... Toronto time). The date of the ... The Meeting will reconvene at the offices of the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... pharmaceutical market is one of the most ... its absolute size, plus a growing economy and increasing ... Business Monitor International. The Russian market is set to ... market, with growth estimates around 10-15% annually reaching an ... About Green Cross Green Cross provides ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Aug. 20 Advanced Cell,Technology, Inc. (OTC Bulletin ... conditions, it plans to privately offer up to ... timing of the,closing of the offering will be ... are expected to be used to fund working ...
... CEO Mark McDade to resign for personal reasons ... BioPharma, Inc.,(PDL) (Nasdaq: PDLI ) today announced ... executive officer (CEO), Mark McDade,found no credible evidence ... by McDade to corroborate the various allegations,investigated. The ...
... Supplier Presents Today at Small Cap Financial ... ... ), a leading provider of nitinol and polymer components to the,medical device ... for the fourth fiscal,quarter ended June 30, 2007, an increase of over ...
Cached Biology Technology:Advanced Cell Technology Announces Proposed Financing 2Advanced Cell Technology Announces Proposed Financing 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 2Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 3Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue 4
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Iris Biometrics - Global Strategic Business Report" ... worldwide markets for Iris Biometrics in US$ Thousands. The report ... , Japan , Europe ... East , and Latin America . ...
(Date:3/17/2015)...  MecklerMedia Corporation (OTCQX: MECK) announced its ... ever held in New York City ... 2015 at the Javits Convention Center. ... Acorn Product Development; Axis NJ; c-Link Systems; CoroWare; ... NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; RocketFarm ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... study, published in the March issue of Human Nature ... difference in their subjective ratings of photos of men when ... who did not have sexual partners spent more time evaluating ... No such difference was found between men who had sexual ...
... , This release is available in <A ... spread and devastating natural disaster across the globe. It ... annual damage of about 1.5 billion. The figure is ... few years (Association of British Insurers). Floods that took ...
... of environmental change? Evolvequickly. A new article in The ... new habitats developed new and advantageous traits in just a ... to look at adaptation and survival in a wild population. ... the University of California, Riverside studied 200 guppies that had ...
Cached Biology News:Single women gaze longer 2Next-generation software system for flood warning and risk analysis to be developed 2When evolution is not so slow and gradual 2
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White lyophilized ... GAS. A cell-permeable, reversible inhibitor of γ-secretase. ... (ED 50 = 2.6 μM) ... = 2.7 μM) in HEK293 cells stably ...
...
Biology Products: